Al., 2008. American Heart Association American Stroke Association [PDF]

Citation preview

RASIO APO B/APO A1 SEBAGAI FAKTOR RISIKO STROKE ISKEMIK Rahma Yuantari Universitas Gadjah Mada, 2014 | Diunduh dari http://etd.repository.ugm.ac.id/



DAFTAR PUSTAKA Adams, R., Albers, G., Alberts, M.J., Benevante, O., Furie, K., Goldstein, L.B., et al., 2008. American Heart Association; American Stroke Association Council on Stroke;Council on Cardiovascular Radiology and Intervention, American Academy of Neurology. Update to AHA/ASA Recommendation for The Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack. Stroke 39:1647-1652 Adams, H.P., Bendixen, B.H., Kapelle, L.J., et al., 1993. Classification of subtype of acute ischemic stroke for the TOAST Investigators. Stroke 24:35–7. Anonim._1. APOAT, Tina-quant Apolipoprotein A1 ver.2. Cobas Anonim._2. APOBT, Tina-quant Apolipoprotein B ver.2. Cobas Badimón, L., Vilahur, G., Padró, T., 2009. Lipoproteins, Platelets, and Atherothrombosis. Rev Esp Cardiol 62(10):1161-78 Baluch, U.T., Kiani, I., Zaib-un-nisa, Badshah, M., 2008. Association of Dyslipidemia and Ischemic Stroke. Ann Pak Inst Med Sci. 4(3): 165-167 Banerjee, C., Moon, Y. P., Paik, M. C., 2012. Duration of diabetes and risk of ischeamic stroke. The NorthernManhattan Study. Stroke 43:1212–1217 Barter, P. J., Nicholls, S., Rye, K.-A., Anantharamaiah, G. M., Navab, M., Fogelman, A. M., 2004. Antiinflammatory Properties of HDL. Circ Res 95(8):764-772. Bhatnagar, D., Durrington, P.N., 2000. Measurement and Clinical Significance od Apolipoprotein A-1 and B. In Handbook of Lipoprotein Testing 2nd edition. American Association for Clinical Chemistry. Inc. Brainin, M., Heiss, W., 2010. Textbook of Stroke Medicine. Cambridge University Press, Cambridge. Burtis, C.A., Ashwood, E.R., Bruns, D.E., 2008. Tietz Fundamental of Clinical Chemistry. 6th ed. Saunders, Elsevier, Missouri. p201-228 Castilla-Guerra, L., Fernandez-Moreno, M.D., 2007. Stroke in diabetic patients: is it really a macrovascular complication? Stroke 38(10):e106 Chien, K., Sung, F., Hsu, H., Su, T., Lin, R., Lee, Y., 2002. Apolipoprotein A-I and B and Stroke Events in a Community-Based Cohort in Taiwan. Stroke 33:39-44. Cooper, G.R, Henderson, L.M., Smith, S.J., Hannon, W.H., 1991. Clinical applications and standardization of apolipoprotein measurements in the diagnostic workup of lipid disorders. Clin Chem 37: 619–20 Corrigan, M.L., Escuro, A.A., Kirby, D.F., 2013. Handbook of Clinical Nutrition and Stroke. Humana Press, Springer Science & Business Media, New York. Derdeyn, C.P., 2007. Mechanisms of ischemic stroke secondary to large artery atherosclerotic disease. Neuroimaging Clin N Am 17(3):303–11 Di Tullio., M.R., Homma, S., Jin, Z., Sacco, R.L.,2008. Aortic Atherosclerosis, Hypercoagulability, and Stroke : The APRIS (Aortic Plaque and Risk of Ischemic Stroke) Study. J Am Coll Cardiol 52(10):855–861



70



RASIO APO B/APO A1 SEBAGAI FAKTOR RISIKO STROKE ISKEMIK Rahma Yuantari



71



Universitas Gadjah Mada, 2014 | Diunduh dari http://etd.repository.ugm.ac.id/



Dwinnel, B.G., Anderson, R.J.,_. Diagnostic Evaluation of The Patient with Acute Renal Failure. Available form http://www.cybernephrology.ualberta.ca/cn /Schrier/Volume1/chap12/ADK1_12_1-3.pdf Fisher, M., 2009. Handbook of Clinical Neurology : Clinical Manifestation and pathogenesis. New York, Elsevier Inc. Ghofir, A. 2011. Manajemen Stroke, Evidence Based Medicine. Pustaka Cendekia Press Giraldo, E.A., 2013. Overview of Stroke. [Cited Februari 1st, 2014] Available from http://www.merckmanuals.com/professional/neurologic_disorders/stroke_ cva/overview_of_stroke.html Goldstein, L.B., Bushnell, C.D., Adams, R.J., Appel, L.J., Braun, L.T., Chaturvedi, S., 2011. Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals. Stroke 42:517-584 Grundy, S.M., Becker, D., Clark, R.T, Cooper, R.S., Denke, M.A, Howard, J.W., et al., 2001. Executive Summary. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No.013670. Hahm, C., Hong, K., 2012. Apolipoprotein B/A1 Ratio as Risk Factor for Cerebral Ischemic Stroke. Ewha Med J. 35(1):21-25 Hamidon, B.B., Raymond, A.A., 2003. Risk Factors and Complications of Acute Ischaemic Stroke Patients' at Hospital Universiti Kebangsaan Malaysia (HUKM). Med J Malaysia 58(4):499-505 Han, C.I., Campbell, G.R., Campbell, J.H., 2001. Circulating bone marrow cells can contribute to neointimal formation. J Vasc Res 38: 113–9. Han, J., Bae, H., Wong, L.K.S., 2011. Pathophysiology and Mechanisms Whereby Hypertension May Cause Stroke. In Hypertension & Stroke. Humana Press, New York, USA. p77-94 Harding, S.A., Sarma, J., Josephs, D.H., Cruden, N.L., Din, J.N., Twomey, P.J., et al., 2004. Upregulation of the CD40/CD40 Ligand Dyad and PlateletMonocyte Aggregation in Cigarette Smokers. Circulation 109:1926-1929 Hilbert, T., Lifshitz, M.S., 2007. Lipids and Dyslipoproteinemia. In Henry's Clinical Diagnosis and Management by Laboratory. McPherson RA. New York, Elsevier Inc. p123-341. Holme, I., Aastveit, A.H., Hammar, N., Jungner, I., Walldius, G., 2009. Relationships between lipoprotein components and risk of ischaemic and haemorrhagic stroke in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 265: 275–287. Howard, G., Wagenknecht, L.E., Burke, G.L., Diez-Roux, A., Evans, G.W., McGovern, P., et al., 1998. Cigarette smoking and progression of atherosclerosis–The atherosclerosis risk in communities (ARIC) study. J Am Med Assoc 279: 119-124 Hyka, N., Dayer, J.M., Modoux, C., Kohno, T., Edwards, C. K., Roux-Lombard, P., Burger, D., 2001. Apolipoprotein A-I inhibits the productionof interleukin-1 β and tumor necrosis factor-α by blockingcontact-



RASIO APO B/APO A1 SEBAGAI FAKTOR RISIKO STROKE ISKEMIK Rahma Yuantari



72



Universitas Gadjah Mada, 2014 | Diunduh dari http://etd.repository.ugm.ac.id/



mediated activation of monocytes by T lymphocytes. Blood 97(8):23812389 Indiana Stroke Prevention Task Force. 2006. Recommendation and Guidelines for Recognition and Intervention of Risk Factors for Stroke, Diagnosis and Treatment of Transient Ischemic Attack, Diagnosis and Treatment of Ischemic Stroke Indiyarti, R., 2003. Dampak hiperglikemia terhadap kelangsungan hidup penderita stroke. J Kedokter Trisakti 22(3):105-109 Jungner, I., Marcovina, S.M., Walldius, G., Holme, I., Kolar, W., Steiner, E., 1998. Apolipoprotein B and A-I values in 147 576 Swedish males and females, standardized according to the World Health OrganizationInternational Federation of Clinical Chemistry First International Reference Materials. Clin Chem 44: 1641–9. Klick, R.L. 1997. Decision Making In The Clinical Laboratory: A Quantitative And Statistical Approach For Methods Evaluation. Med TechNet Online Continuing Education for the Clinical Laboratory Professional.p1-27 Kurth, T., Everett, B.M., Buring, J.E., Kase, C.S., Ridker, P.M., Gaziano, J.M., 2007. Lipid levels and the risk of ischemic stroke in women. Neurology. 68:556 –562. Kurniasih, R., Wijaya, A., 2002. Peran Radikal Bebas Pada Iskemia-Reperfusi Serebral atau Miokardium. Forum Diagnosticum, Laboratorium Klinik Prodia. Koren-Morag, N., Goldbourt, U., Graff, E., Tanne, D., 2008. Apolipoprotein B and A1 and the risk of ischemic cerebrovascular events in patients with pre-existing atherothrombotic disease. J Neurol Sci 270:82-87 Kostapanos, M.S., Christogiannis, L.G., Bika, E., Bairaktari, E.T., Goudevenos, J.A., Elisaf, M.S., et al., 2010. Apolipoprotein B-to-A1 Ratio as a Predictor of Acute Ischemic Nonembolic Stroke in Elderly Subjects. J Stroke Cerebrovasc Dis 19(6): 497-502 Kottke-Marchant K., Davis H.B., 2012. Laboratory Hematology Practice. International Society for Laboratory Hematology. First edition. WileyBlackwell. United Kingdom. Labeur, C., Shepherd, J., Rosseneu, M., 1990. Immunological Assays of Apolipoproteins in Plasma: Methods and Instrumentation. Clin Chem 36(4):591-597 Lima, L.M., Carvalho, M.G., Sabino, A.P., Mota, A.P.L., Fernandes, A.P., Sousa, M.O., 2007. Apo B/Apo A-I Ratio in Central and Peripheral Arterial Diseases. Arq Bras Endocrinol Metab 51(7):1160-1165 Lisabeth, L.D., Beiser, A.S., Brown, D.L., Murabito, J.M., Kelly-Hayes, M, Wolf P.A., 2009. Age at natural menopause and risk of ischemic stroke: the Framingham heart study. Stroke 40(4):1044–9. Li, Z., Xu, Y., Tan, S., Song, B., Liu, M., 2009. Study of plasma levels of ApoA-I and Apo B for prognosis of acute ischemic stroke. Life Sci J 6(2): 51 – 56 Lawrence, W.K.S., Caplan, L.R., Jong, K.S., 2008. Stroke Mechanism. In: Intracranial Atherosclerosis. Singapore: Blackwell Publishing Ltd, p19-21



RASIO APO B/APO A1 SEBAGAI FAKTOR RISIKO STROKE ISKEMIK Rahma Yuantari



73



Universitas Gadjah Mada, 2014 | Diunduh dari http://etd.repository.ugm.ac.id/



Lewis, G.F., Rader, D.J., 2005. New Insights Into the Regulation of HDL Metabolism and Reverse Cholesterol Transport. Circ Res 96:1221-32 Madjid, M., Awan, I., Willerson, J.T., Cascells, W., 2004. Leukocyte Count and Coronary Heart Disease implications for risk assessment. J Am Coll Cardiol 44:1945-56 Manduteanu, I., Simionescu, M., 2012. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med 16(9):1978-1990. Marcovina, S.M., Albers, J.J., Henderson, L.O., Hannon, W.H., 1993. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem 39: 773–81 Marcovina, S.M., Albers J.J., Kennedy, H., Mei, J.V., Henderson, L.O., Hannon W.H., 1994. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference materials. Clin Chem 40:586–92. Marcovina, S.M, Packard, C.J., 2006. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Int Med 259: 437– 446 Mayes, P.A., 1997. Pengangkutan dan Penyimpanan Lipid. Dalam Biokimia Harper. Edisi 24. Penerbit EGC, Jakarta. McCully, KS., 2009. Chemical Pathology of Homocysteine. IV. Excitotoxicity, Oxidative Stress, Endothelial Dysfunction, and Inflammation. Annals of Clinical & Laboratory Science 39(3):219-232 McQueen, M.J., Hawken, S., Wang, X., Ounpuu, S., Sniderman, A., Probstfield, J., 2008. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a casecontrol study. Lancet 372:224–233 Misbach J., 1999. Stroke, Aspek Diagnostik, Patofisiologi, Manajemen. Jakarta. Balai Penerbit FKUI, p45-46. Mora, S., Rifai, N., Buring, J.E, Ridker, P.M., 2008. Fasting Compared with Nonfasting Lipids and Apolipoproteins for Predicting Incident Cardiovascular Events. Circulation 118(10): 993–1001 Nurulita, A., Bahrun, U., Arif, M., 2011. Perbandingan Kadar Apolipoprotein B Dan Fraksi Lipid Sebagai Faktor Resiko Sindrom Koroner Akut. JST Kesehatan (1)1:94-100 O’Donnell, M.J., Xavier, D., Liu, L., Zhang ,H., Chin, S.L., Rao-Melacini, P. et al., 2010. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet 376; 112–23 Olofsson, S., Borén. J., 2012. Apolipoprotein B Secretory Regulation by Degradation. Arterioscler Thromb Vasc Biol. 32:1334-1338 Olofsson, S., Wiklun, O., Boren, J., 2007. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for



RASIO APO B/APO A1 SEBAGAI FAKTOR RISIKO STROKE ISKEMIK Rahma Yuantari



74



Universitas Gadjah Mada, 2014 | Diunduh dari http://etd.repository.ugm.ac.id/



intervention against cardiovascular disease. Vasc Health Risk Manag 3(4):491–502 Paul, S.L, Thrift, A.G., Donnan, G.A., 2004. Smoking as a Crucial Independent Determinant of Stroke. Tobacco Induced Diseases 2(2): 67-80 Porsch-Ozcurumez, M., Westphal, S., Luley, C., 2001. Measurement of Low Apolipoprotein Concentrations by Optimized Immunoturbidimetric Applications. Clin Chem 47(3):594-597 Pusparini., 2002. Homosistein faktor risiko baru (non tradisional) penyakit kardiovaskuler. J Kedokter Trisakti 21(1):31-39 Rifai, N., King, M.E., 1986. Immunoturbidimetric assays of apolipoproteins A, AI, AII, and B in serum. Clin Chem 32(6):957–961 Riset Kesehatan Dasar (RISKESDAS) Indonesia., 2007. Laporan Nasional tahun 2007 Badan Penelitian dan Pengembangan Kesehatan Depkes RI Sabino, A.P., Sousa, M.D.O., Lima, L.M., Ribeiro, D.D., Dusse, L.M.S., et al., 2008. ApoB/ApoA-I Ratio In Young Patients With Ischemic Cerebral Stroke Or Peripheral Arterial disease. Translational Research 152:113– 118 Sacco, R.L., Kasner, S.E., Broderick, J.P., Caplan, L.R., Connors, J.J., Culebras, A., et al., 2013. An Updated Definition of Stroke for the 21st Century : A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 44:2064-2089 Sastroasmoro,S., 2008, Dasar-dasar Metodologi Penelitian Klinis, Sagung Seto, Jakarta Schmidt, C., Fagerberg, B., Wikstrand, J., Hulthe, J., 2006. ApoB/apoA-I ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis 189:178–185. Setyopranoto, I., 2012. Odem Otak pada Pasien Stroke Iskemik Akut. Penerbit Fakultas Kedokteran Universitas Gadjah Mada, Yogyakarta Shah, P.K., 2003. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41:S15–22 Shao-Hua, W., Zi-lin, S., Xiong-Zhong, R., Yi-Jing, G., Yao, W., Hui, J., et al., 2009. Dyslipidemia among diabetic patients with ischemic stroke in a Chinese hospital. Chinese Med J 122(21):2567-72. Shilpasree, A.S., Sahukar, S., Murthy, J., Kumar, K., 2013. A study of serum Apolipoprotein A, Apolipoprotein B and lipid profile in stroke. J Clin and Diag Res 7(7): 1303-1306 Sherman, K.E., Alanine aminotransferase in clinical practice. Arch Intern Med. 1991;151:260–5 Simionescu, M., 2007. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler Thromb Vasc Biol 27: 266– 74. Smith, S.J., Cooper, G.R., Henderson, L.O., Hannon, W.H., 1987. The Apolipoprotein Standardization Collaborating Group. An international collaborative study on standardization of apolipoproteins A-I and B. Part I. Evaluation of a lyophilized candidate Reference and Calibration Material. Clin Chem 33:2240-9



RASIO APO B/APO A1 SEBAGAI FAKTOR RISIKO STROKE ISKEMIK Rahma Yuantari



75



Universitas Gadjah Mada, 2014 | Diunduh dari http://etd.repository.ugm.ac.id/



Soyama, Y., Miura, K., Morikawa, Y., Nishijo, M., Nakanishi, Y., Naruse, Y., et al., 2003. High-Density Lipoprotein Cholesterol and Risk of Stroke in Japanese Men and Women: The Oyabe Study. Stroke 34:863-868 Tabas, I., Tall, A., Accili, D., 2010. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ Res 106: 58–67. Teramoto, T., Sasaki, J., Ueshima, H., Egusa, G., Kinoshita, M., Shimamoto, K, et al., 2007. Diagnostic Criteria for Dyslipidemia : Executive Summary of Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases for Japanese. J Atheroscler Thromb 14:155-158 Tjandrawinata, R.R., 2013. Terapi Masa Depan Melalui Penghambatan atau Downregulation Ekspresi Cholesteryl Ester Transfer Protein (CETP) dalam Menurunkan Risiko Penyakit Kardiovaskular. Medicinus 26(1):5-10 Uddin, M.J., Alam, B., Jabbar, M.A., Mohammad, Q.D., Ahmed, S., 2009. Association of lipid profile with ischemic stroke. Mymensingh Med J 18(2):131-5 Urbanus, R.T., Siegerink, B., Roest, M., Rosendaal, F.R., De Groot, P.G., Algra, A., 2009. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. The Lancet Neurology 8(11):998 – 1005 Vardas, P.E., Mavrakis, H.E., 2004. Atrial Fibrillation and Heart Failure. Hellenic J Cardiol 45: 277-281 Wahjoepramono, E.J, 2005. Stroke Tata Laksana Fase Akut. Fakultas Kedokteran Universitas Pelita Harapan, Jakarta Walldius, G., Jungner I., 2004. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 255: 188-205. Walldius, G., Jungner, I., 2006. The apo B/apo A-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid lowering therapy — a review of the evidence. J Intern Med 259:493-519 Walldius, G., Aasteveit, A.H., Junger, I., 2006. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Int Med. 259: 259–266 Wasan, K.M., Brocks, D.R., Lee, S.D., Sachs-Barrable, K., Thornton, S.J., 2008. Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat Rev Drug Disc 7:84-9 Zakhari, S., 1997. Alcohol and the cardiovascular system: molecular mechanisms for beneficial and harmful action. Alcohol Health Res World 21(1):21–9. Zhang, Y., Tuomilehto, J., Jousilahti, P., Wang, Y., Antikainen, R., Hu, G., 2012. Total and High-Density Lipoprotein Cholesterol and Stroke Risk. Stroke. 43:1768-1774